Loading clinical trials...
Loading clinical trials...
Phase Ia/Ib, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, A Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotinib (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors of Epithelial Cell Origin
Conditions
Interventions
RO5479599
Cetuximab
+2 more
Locations
12
Denmark
Rigshospitalet, Onkologisk Klinik
København Ø, Denmark
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Academ Ziekenhuis Groningen; Medical Oncology
Groningen, Netherlands
Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed
Rotterdam, Netherlands
Utrecht University Medical Centre; Dept of Medical Oncology and UPC
Utrecht, Netherlands
National Cancer Center
Gyeonggi-do, South Korea
Start Date
December 1, 2011
Primary Completion Date
February 1, 2016
Completion Date
February 1, 2016
Last Updated
January 27, 2017
NCT07213804
NCT07159659
NCT07169851
NCT00026884
NCT06662786
NCT07481851
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions